Published in J Inherit Metab Dis on January 01, 2001
Modest phenotypic improvements in ASA-deficient mice with only one UDP-galactose:ceramide-galactosyltransferase gene. Lipids Health Dis (2006) 0.75
A historical perspective of the glycosphingolipids and sphingolipidoses. Philos Trans R Soc Lond B Biol Sci (2003) 0.75
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 10.40
Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A (1993) 9.17
A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol (1988) 7.87
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 7.76
Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol (1991) 6.19
Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol (1990) 5.81
Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med (1967) 5.63
Construction and use of a safe and efficient amphotropic packaging cell line. Virology (1988) 5.58
High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol (1995) 4.59
Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J (1992) 4.36
Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol (1998) 4.17
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 4.02
A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A (1996) 3.89
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Transfer of genes to humans: early lessons and obstacles to success. Science (1995) 3.64
High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res (1998) 3.56
An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med (1995) 3.42
Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med (1999) 3.11
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science (1995) 2.79
Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med (1996) 2.73
Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet (1998) 2.65
Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol (2000) 2.58
Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A (1986) 2.51
Human gene therapy. Nature (1998) 2.50
The role of the adenovirus protease on virus entry into cells. EMBO J (1996) 2.44
alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A (1997) 2.43
Immune response to green fluorescent protein: implications for gene therapy. Gene Ther (1999) 2.27
FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID. J Biol Chem (1963) 2.24
Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet (1981) 2.22
Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol (1997) 2.19
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet (2001) 2.13
Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci U S A (1994) 2.12
Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet (1995) 2.06
Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A (2000) 2.00
Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med (1973) 1.94
Update on adenovirus and its vectors. J Gen Virol (2000) 1.93
Adenovirus vectors for gene delivery. Curr Opin Biotechnol (1999) 1.89
Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med (2001) 1.85
Virus treatment questioned after gene therapy death. Nature (1999) 1.81
Use of green fluorescent protein variants to monitor gene transfer and expression in mammalian cells. Nat Biotechnol (1996) 1.70
Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature (1993) 1.55
Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med (1999) 1.54
Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood (1991) 1.52
Glucose-dependent insulin release from genetically engineered K cells. Science (2000) 1.52
Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science (1992) 1.49
Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet (2000) 1.48
Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A (1997) 1.48
Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today (2000) 1.45
Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci U S A (2001) 1.40
Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol (2000) 1.39
Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Ther (1999) 1.39
A proliferation switch for genetically modified cells. Proc Natl Acad Sci U S A (1997) 1.38
Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther (1999) 1.37
Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci U S A (2000) 1.33
Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc Natl Acad Sci U S A (1994) 1.27
Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J Virol (1998) 1.25
Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes. Proc Natl Acad Sci U S A (1979) 1.21
Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci U S A (1996) 1.21
Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest (2000) 1.20
Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease. J Biol Chem (1987) 1.19
Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci U S A (1999) 1.19
Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J Virol (1999) 1.17
Umbilical cord blood transplantation: overview of the clinical experience. Blood Cells (1994) 1.15
Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther (2000) 1.15
Bone marrow transplantation for Hurler syndrome: assessment of metabolic correction. Birth Defects Orig Artic Ser (1986) 1.08
Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. Hum Gene Ther (1995) 1.07
Expression of functional interleukin-2 receptors in human light chain/Tac transgenic mice. Nature (1988) 1.06
pH-sensitive, cationic liposomes: a new synthetic virus-like vector. Nat Biotechnol (1996) 1.06
Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther (1999) 1.05
Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins. J Virol (1998) 1.04
Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood (2000) 1.04
Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human beta-globin in engrafted mice. Proc Natl Acad Sci U S A (2000) 1.03
Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood (1999) 1.02
Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease. Hum Gene Ther (1999) 1.01
Virosomes: cationic liposomes enhance retroviral transduction. Nat Biotechnol (1996) 0.96
Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides. Gene Ther (1998) 0.95
Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J Virol (1999) 0.95
Non-viral gene therapy. Curr Opin Biotechnol (1994) 0.95
Human beta interferon scaffold attachment region inhibits de novo methylation and confers long-term, copy number-dependent expression to a retroviral vector. J Virol (2000) 0.92
Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease. Hum Pathol (1990) 0.92
Preselective gene therapy for Fabry disease. Proc Natl Acad Sci U S A (2001) 0.92
Improvements in adenoviral vector technology: overcoming barriers for gene therapy. Clin Genet (2000) 0.91
Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp Hematol (1999) 0.89
Detection and isolation of gene-corrected cells in Gaucher disease via a fluorescence-activated cell sorter assay for lysosomal glucocerebrosidase activity. Blood (1997) 0.88
Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest. Hum Gene Ther (2000) 0.85
In vivo studies on glycosphingolipid metabolism in porcine blood. J Biol Chem (1970) 0.84
Selection of retrovirally transduced cells to enhance the efficiency of gene therapy. Proc Assoc Am Physicians (1997) 0.84
Human gene marker/therapy clinical protocols. Hum Gene Ther (2000) 0.84
Expanded-capacity adenoviral vectors--the helper-dependent vectors. Mol Med Today (1999) 0.83
Viral vectors for gene therapy of hematopoietic cells. Immunotechnology (1997) 0.82
Gene transfer and expression of human alpha-galactosidase from mouse muscle in vitro and in vivo. Gene Ther (1997) 0.80
Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector. J Hum Genet (2000) 0.78
Targeted gene delivery: a two-pronged approach. Crit Rev Ther Drug Carrier Syst (2000) 0.78
Redesigning small molecule-protein interfaces. Curr Opin Struct Biol (1998) 0.78
Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther (1999) 0.77
Retrovirus-mediated transfer of human alpha-galactosidase A gene to human CD34+ hematopoietic progenitor cells. Hum Gene Ther (1999) 0.76
Gene therapy for lysosomal storage disorders with neuropathology. J Am Soc Nephrol (2000) 0.76
Formation of high affinity IL-2 receptors is dependent on a nonligand binding region of the alpha subunit. J Immunol (1994) 0.76
Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc Natl Acad Sci U S A (1994) 1.98
Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci U S A (2000) 1.33
A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signalling. Biochem J (2001) 1.09
Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease. Hum Gene Ther (1999) 1.01
Retinoic acid induction of major histocompatibility complex class I genes in NTera-2 embryonal carcinoma cells involves induction of NF-kappa B (p50-p65) and retinoic acid receptor beta-retinoid X receptor beta heterodimers. Mol Cell Biol (1993) 1.00
Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther (2006) 0.99
Recombinant thyroid hormone receptor and retinoid X receptor stimulate ligand-dependent transcription in vitro. Proc Natl Acad Sci U S A (1994) 0.92
Preselective gene therapy for Fabry disease. Proc Natl Acad Sci U S A (2001) 0.92
Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Proc Natl Acad Sci U S A (1995) 0.91
Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol Cell Endocrinol (1997) 0.89
Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp Hematol (1999) 0.89
Lentivirus IL-10 gene therapy down-regulates IL-17 and attenuates mouse orthotopic lung allograft rejection. Am J Transplant (2013) 0.85
Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer. Cancer Gene Ther (2012) 0.84
Stress-induced apoptosis is not mediated by endolysosomal ceramide. FASEB J (2000) 0.84
Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes. Gene Ther (2012) 0.82
Retinoid X receptor beta and peroxisome proliferator-activated receptor activate an estrogen response element. Recent Prog Horm Res (1995) 0.80
Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model. Gene Ther (2011) 0.79
Transduction and transplantation of spermatogonia into the testis of ram lambs through the extra-testicular rete. Reprod Domest Anim (2008) 0.77
Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells. Cancer Gene Ther (2008) 0.76
Novel application of lentiviral vectors towards treatment of graft-versus-host disease. Expert Opin Biol Ther (2009) 0.75
Characterization of the chimeric retinoic acid receptor RARalpha/VDR. Leukemia (1998) 0.75